Neurocrine Biosciences (NBIX) Return on Capital Employed (2011 - 2026)

Neurocrine Biosciences has reported Return on Capital Employed for 16 years, with the latest figure at 20.04% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 448.0% year-over-year to 20.04%; the trailing twelve-month figure through Mar 2026 stood at 20.04% (up 448.0% YoY), and the FY2025 full-year result was 18.04%, down 112.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 20.04%, up from 16.71% in the prior quarter.
• The five-year high for Return on Capital Employed was 20.04% in Q1 2026, with the low at 3.69% in Q2 2022.
• Historically, Return on Capital Employed has averaged 12.98% across 5 years, with a median of 15.27% in 2025.
• Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 508 bps — and 2024, when it surged 1091 bps.
• Neurocrine Biosciences' Return on Capital Employed stood at 14.49% in 2022, then decreased by 28 bps to 10.48% in 2023, then soared by 75 bps to 18.29% in 2024, then retreated by 9 bps to 16.71% in 2025, then increased by 20 bps to 20.04% in 2026.
• The last three Return on Capital Employed figures came in at 20.04% (Q1 2026), 16.71% (Q4 2025), and 16.0% (Q3 2025), per Business Quant data.